Shares of Dr Reddy's Laboratories jumped 5.3 per cent on Thursday to Rs 1,217 apiece, making it the top gainer in the Nifty 50 and the BSE 100 indices. By comparison, the Nifty 50 was up 0.53 per cent at 25,289.
Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.
The Bengaluru police have launched a probe into a cyber fraud case where hackers allegedly infiltrated the official email communication between city-based Group Pharmaceuticals and Dr Reddy's Laboratories, Hyderabad, successfully diverting a payment of Rs 2.16 crore to a fraudulent account.
Pharma major Dr Reddy's Laboratories delivered a muted operational performance in the fourth quarter of financial year 2024-25 (Q4FY25), even as revenue growth remained healthy. Lower gross margin performance and muted domestic growth are key concerns. Most brokerages have a "Sell" or "Reduce" rating as there are uncertainties related to the development of a new product portfolio and the launch timelines.
Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after analysts remained cautious on the company's Q3 performance and differed on its growth outlook. DRL's Q3 performance was viewed as subdued by some analysts when they adjusted it for one-time grants and incomes that the company received during the quarter.
Buoyant domestic sales are expected to lift revenues for pharma companies by 8-11 per cent in Q3FY26, even as declining generic Revlimid (cancer drug) sales in the US remain a key drag. Most brokerages forecast a modest 2-4 per cent growth in profit after tax (PAT) for the quarter. Hospitals and diagnostics companies, meanwhile, are likely to post much stronger numbers, with revenues seen growing 20-22 per cent year-on-year (Y-o-Y).
Avigan comes in a complete therapy pack of 122 tablets with a two-year shelf life.
The patent relates to the manufacturing process for the active ingredient in Sanofi-Aventis' Allegra and Allegra-D drug products. Both Dr Reddys and Sandoz are known to be marketing these products in the US.
Dr Reddy's, which has tied up with Russian Direct Investment Fund for Sputnik V in India, soft launched the vaccine in India in May 2021, after receiving Emergency Use Authorisation in April 2021.
Dr Reddy's Laboratories on Thursday launched diabetic foot ulcers treatment drug, Plermin, for patients who develop food ulcers due to neuropathy.
In the cataclysmic fall by techs led by Infosys, the sudden downturn by Dr Reddy's Labs late Friday went virtually innoticed.
GlaxoSmithKline has filed a lawsuit in a United States court against Dr Reddy's Laboratories alleging infringement of patent rights of a generic version of 'Imitrex' drug, used for the treatment of migraine.
Dr.Reddy's Laboratories has acquired Trigenesis Therapeutics Inc, a United States based privately owned dermatology company, with a total investment outlay of $11 million.
Pharma major Dr Reddy's Laboratories has opposed the parliamentary Standing committee's recommendations of increasing the number of drugs under price control and cap on profit margins of all medicines.
Dr Reddys Laboratories Ltd and Leiner Health Products signed a 15-year product development and marketing agreement for for Dr Reddys over-the-counter drug products.
Hyderabad-based pharma company Dr Reddy's Laboratories (DRL) has acquired Jet Generici Srl, a company engaged in the sale of generic finished dosages in Italy. Financial terms and conditions of the transaction were not disclosed. The deal has been completed through Dr Reddy's Italian subsidiary, Reddy Pharma Italia, which has been engaged in building a pipeline of registrations since its incorporation.
Dr Reddy's Laboratories has filed an Abbreviated New Drug Application with the United States Food and Drug Administration for Levetiracetam tablets, 250, 500 and 750 mg.
Dr Reddy's Laboratories has completed acquisition of betapharm, its mega overseas deal valued at 480 million (Rs 2,668 crore).\n
On December 27 last year, Pfizer had moved to the US District Court for the District of Delaware against Dr Reddy's Laboratories Ltd and Dr Reddy's Laboratories Inc for infringement of Pfizer's crystalline atorvastatin patent.
Dr Reddy's Laboratories & Strides Arcolabs are at a risk of raiders as their promoter holdings are less than 26%. Promoters of Dr Reddy's have 25.15% stake as on Dec 31, 2007 and the share value of the company has dipped 19.9 per cent since January 1 this year. The Bangalore-based Strides Arcolab had only 18.82% promoter-holding as on Dec 31, 2007. The stock price of the company has gone down 34% in the same period. The promoters are taking steps to correct the situation.
Dr Reddy's Laboratories has been awarded the 'WorldStar 2004 Award' by the World Packaging Organisation for its anti-counterfeit and patient protection packaging.
India's generic drug manufacturer, Dr Reddy's Laboratories, suffered a setback when a US' Court of Appeals ruled that it infringed on Pfizer Pharmaceutical company's patent for the blood pressure medicine Norvasc.
The company will supply the drug to major government as well as private hospitals across India, Dr Reddy's said in a regulatory filing.
The plant and associated facilities focus on manufacturing or packaging Amoxicilin-based products, which include semi-synthetic penicillin
Hindustan Unilever (HUL) has topped the Perpetual Capital Hurun India Impact 50 - 2026 list with 53.9 points (on the scale of 0-100), reflecting a strong performance across key sustainable development goals (SDGs), including climate, water, circularity, gender and biodiversity.
Dr Reddy's shrugged off recent volatility on Wednesday and moved tenaciously on filing new gernerics with the US FDA.
Dr Reddy's Labs gave the market reason to devalue the scrip further after it announced that it was dropping three compounds from its research pipeline.
Kejriwal's announcement came after Deputy Chief Minister Manish Sisodia earlier this week claimed that Covaxin manufacturer Bharat Biotech has refused to provide additional doses to the national capital.
Drug maker Dr Reddy's Laboratories on Wednesday said it was looking out for partnerships to expand its presence in Japan.
Dr Reddy's Laboratories on Wednesday said it has acquired GlaxoSmithKline's US penicillin manufacturing facility and the rights to the Augmentin and Amoxil brands in the United States for an undisclosed sum.
Dr Reddy's Laboratories (DRL) is set to acquire Haleon's global portfolio of consumer healthcare brands in the nicotine replacement therapy (NRT) category outside of the US. DRL will pay a total consideration of 500 million, including an upfront cash consideration of 458 million and contingent cash payments up to 42 million based on performances in CY25 and CY26. DRL will acquire the portfolio through the purchase of shares of Northstar Switzerland SARL, a Haleon group firm.
The Indian drug industry's dream of coming out with an own new chemical entity or an originally researched new drug has received a big boost. Balaglitazone, the diabetic drug molecule being developed by Dr Reddy's Laboratories, has showed encouraging results in the final lap of human clinical trials.
Some time in mid-March, Dr Reddy's Laboratories will reach a new landmark: Its sales in India will cross the Rs 1,000-crore mark.
The US Drug maker requested the court to pass an order to restrain DRL from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing DRL's generic paricalcitol injectable products prior to the expiration of said patents.
Dr Reddy's on Monday said it would acquire Switzerland-based Roche's bulk drug business in Mexico for $59 million.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances